|MDACC Study No:||2009-0179 (clinicaltrials.gov NCT No: NCT00966693)|
|Title:||Phase I/II Study of Lenalidomide (Revlimid), Thalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma|
|Principal Investigator:||Jatin J. Shah|
|Treatment Agent:||Dexamethasone; Lenalidomide; Thalidomide|
|Study Description:||The goal of the Phase I portion of this clinical research study is to find the |
highest tolerated dose of the combination of thalidomide, lenalidomide, and
dexamethasone that can be given to patients with relapsed or refractory MM.
The goal of the Phase II portion of this study is to learn if the drug
combination can help to control the disease.
The safety of the drug combination will be studied in both phases.